Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. More Details
Flawless balance sheet with solid track record and pays a dividend.
Share Price & News
How has Ajanta Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AJANTPHARM has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AJANTPHARM exceeded the Indian Pharmaceuticals industry which returned 48.4% over the past year.
Return vs Market: AJANTPHARM exceeded the Indian Market which returned 2.8% over the past year.
Price Volatility Vs. Market
How volatile is Ajanta Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Much Does Ajanta Pharma's (NSE:AJANTPHARM) CEO Make?
3 weeks ago | Simply Wall StAjanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
1 month ago | Simply Wall StIs Ajanta Pharma Limited (NSE:AJANTPHARM) Popular Amongst Insiders?
Is Ajanta Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AJANTPHARM (₹1605.95) is trading above our estimate of fair value (₹791.08)
Significantly Below Fair Value: AJANTPHARM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AJANTPHARM is poor value based on its PE Ratio (28x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: AJANTPHARM is poor value based on its PE Ratio (28x) compared to the Indian market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: AJANTPHARM is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: AJANTPHARM is overvalued based on its PB Ratio (5.4x) compared to the IN Pharmaceuticals industry average (2.2x).
How is Ajanta Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AJANTPHARM's forecast earnings growth (16.9% per year) is above the savings rate (7.2%).
Earnings vs Market: AJANTPHARM's earnings (16.9% per year) are forecast to grow slower than the Indian market (25.9% per year).
High Growth Earnings: AJANTPHARM's earnings are forecast to grow, but not significantly.
Revenue vs Market: AJANTPHARM's revenue (12.5% per year) is forecast to grow faster than the Indian market (11.4% per year).
High Growth Revenue: AJANTPHARM's revenue (12.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AJANTPHARM's Return on Equity is forecast to be low in 3 years time (19.3%).
How has Ajanta Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AJANTPHARM has high quality earnings.
Growing Profit Margin: AJANTPHARM's current net profit margins (18.9%) are higher than last year (18.3%).
Past Earnings Growth Analysis
Earnings Trend: AJANTPHARM's earnings have grown by 2.2% per year over the past 5 years.
Accelerating Growth: AJANTPHARM's earnings growth over the past year (26.6%) exceeds its 5-year average (2.2% per year).
Earnings vs Industry: AJANTPHARM earnings growth over the past year (26.6%) exceeded the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: AJANTPHARM's Return on Equity (19.3%) is considered low.
How is Ajanta Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: AJANTPHARM's short term assets (₹16.4B) exceed its short term liabilities (₹6.1B).
Long Term Liabilities: AJANTPHARM's short term assets (₹16.4B) exceed its long term liabilities (₹1.1B).
Debt to Equity History and Analysis
Debt Level: AJANTPHARM's debt to equity ratio (1.8%) is considered satisfactory.
Reducing Debt: AJANTPHARM's debt to equity ratio has reduced from 8.5% to 1.8% over the past 5 years.
Debt Coverage: AJANTPHARM's debt is well covered by operating cash flow (982.1%).
Interest Coverage: AJANTPHARM's interest payments on its debt are well covered by EBIT (86.8x coverage).
What is Ajanta Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AJANTPHARM's dividend (0.81%) is higher than the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: AJANTPHARM's dividend (0.81%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).
Stability and Growth of Payments
Stable Dividend: AJANTPHARM's dividend payments have been volatile in the past 10 years.
Growing Dividend: AJANTPHARM's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22.7%), AJANTPHARM's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AJANTPHARM's dividends in 3 years are forecast to be well covered by earnings (23.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yogesh Agrawal (48 yo)
Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd. He has handled various aspects of ...
CEO Compensation Analysis
Compensation vs Market: Yogesh's total compensation ($USD1.45M) is above average for companies of similar size in the Indian market ($USD561.50K).
Compensation vs Earnings: Yogesh's compensation has been consistent with company performance over the past year.
|MD & Executive Director||12.83yrs||₹107.22m||14.49% |
|Joint MD & Director||7.5yrs||₹107.22m||14.49% |
|Executive Vice Chairman of the Board||12.83yrs||₹16.76m||no data|
|Lead Independent Director||3.17yrs||₹751.00k||0.00080% |
|Director of Ajanta Pharma USA Inc.||no data||₹25.50m||no data|
|Chairman of the Board||no data||₹427.00k||0.19% |
|Non Executive Independent Director||no data||₹596.00k||no data|
|Non Executive Independent Director||6.33yrs||₹596.00k||0.00039% |
|Non Executive Independent Director||6.33yrs||₹534.00k||no data|
|Director of Ajanta Pharma Philippines Inc.||no data||no data||0.0043% |
|Director of Ajanta Pharma (Mauritius) Ltd.||no data||no data||no data|
|Director of Ajanta Pharma (Mauritius) Ltd.||no data||no data||no data|
Experienced Board: AJANTPHARM's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AJANTPHARM insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ajanta Pharma Limited's company bio, employee growth, exchange listings and data sources
- Name: Ajanta Pharma Limited
- Ticker: AJANTPHARM
- Exchange: NSEI
- Founded: 1973
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹140.137b
- Shares outstanding: 87.26m
- Website: https://www.ajantapharma.com
Number of Employees
- Ajanta Pharma Limited
- Ajanta House
- 98 Govt. Industrial Area
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|532331||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jun 2000|
|AJANTPHARM||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Jun 2000|
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeut ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 12:44|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.